How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
June 17, 2024 Comments Off
Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly’s diabetes injection Mounjaro and obesity drug Zepbound.
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly’s diabetes injection Mounjaro and obesity drug Zepbound.
Archives
Categories
Archives
Recent Posts
Meta
Categories
Calender